4DMEDICAL LIMITED (ASX: 4DX)
Health care · News and insights
Price unavailable
Latest 4DX announcements
Announcement Insights
4DMedical Reports Record Scan Growth as AGM Rejections Prompt Board Changes
4DMedical reported record quarterly scan volumes, up 61% year on year, and operating revenue growth of 66% in its 28 October update, with software deployed at 724 sites and cash of approximately $243 million. Shareholders rejected the remuneration report and several executive incentive and governance resolutions at the AGM; director Lilian Bianchi then ceased on 28 October, and the company appointed former ResMed CFO Brett Sandercock as an independent director on 16 November, subject to election at the next AGM.
Updated 16 Nov 2026, 10:05 AM Sydney time
Sources
Former ResMed CFO Brett Sandercock joins 4DMedical BoardApplication for quotation of securities - 4DXBecoming a substantial holderPause in TradingResponse to ASX Price QueryFinal Director's Interest Notice -LBApplication for quotation of securities - 4DXAGM Presentation and Chair's addressQuarterly Activity Report and Appendix 4CResults of AGMComments
2026-11-16 · Health care
4DX: $2.19 -4.78% · MC: $1.4B
4DMedical has appointed former ResMed CFO Brett Sandercock as an independent non-executive director, effective immediately. He will chair the Audit and Risk Committee and join the Remuneration and Nomination Committee, bringing more than 30 years of finance leadership in global healthcare technology. Sandercock will stand for election at the company’s next AGM.
Updated 2026-11-16 09:54
Sources
Former ResMed CFO Brett Sandercock joins 4DMedical BoardComments
2026-11-13 · Health care
4DX: $2.30 -0.43% · MC: $1.4B
4DMedical applied to quote 4,000 ordinary shares issued after options were exercised for cash at 75 cents each. The shares add to the company’s quoted capital, following a similar application last month for 101,000 shares from option exercises.
Updated 2026-11-13 16:34
Sources
Application for quotation of securities - 4DXComments
2026-11-05 · Health care
4DX: $2.41 +12.09% · MC: $1.4B
JPMorgan Chase & Co. and its affiliates became a substantial holder in 4DMedical with voting power of just over 5%. Most of the disclosed interest comprises shares on loan through JPMorgan Chase Bank as agent lender, with other interests including securities subject to return under lending agreements and investment management holdings.
Updated 2026-11-05 10:30
Sources
Becoming a substantial holderComments
2026-11-02 · Health care
4DX: $2.60 +6.56% · MC: $1.4B
4DMedical says it believes increased short interest is responsible for recent trading in its shares, and it is unaware of undisclosed information that could explain the activity. ASX queried the company after its shares fell about 27% from the previous close to a low the following day, alongside a significant increase in trading volume. ASX temporarily paused trading pending an announcement before the company released its response.
Updated 2026-11-02 11:06
Sources
Pause in TradingResponse to ASX Price QueryComments
2026-10-30 · Health care
4DX: $2.44 -25.61% · MC: $1.4B
4DMedical disclosed that departing chair Lilian Bianchi had an indirect interest in approximately 599,000 shares when she left the board at the AGM. Separately, the company applied to quote approximately 101,000 shares issued following the exercise of options at $0.75 each.
Updated 2026-10-30 16:25
Sources
Application for quotation of securities - 4DXFinal Director's Interest Notice -LBComments
2026-10-28 · Health care
4DX: $3.43 -4.99% · MC: $1.4B
4DMedical reported record quarterly scan volumes, up 61% on the prior corresponding period, and operating revenue up 66%, with its software now deployed at 724 sites globally. The quarter also brought new U.S. and European customer agreements, while the company reported a cash balance of approximately $243 million at quarter-end. At its AGM, shareholders rejected the remuneration report—triggering a first strike—and several executive incentive and governance resolutions.
Updated 2026-10-28 14:39
Sources
AGM Presentation and Chair's addressQuarterly Activity Report and Appendix 4CResults of AGMComments
Comments